| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1349-7006.2009.01239.X |
| P698 | PubMed publication ID | 19555390 |
| P2093 | author name string | Akiko Furuya | |
| Shinobu Kawamoto | |||
| Hiroshi Ando | |||
| So Ohta | |||
| Masayo Suzuki | |||
| Kazuyasu Nakamura | |||
| Mariko Kato-Nakano | |||
| Naoya Kimoto | |||
| Yuzuru Abe | |||
| Hirofumi Misaka | |||
| P2860 | cites work | Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia | Q30312115 |
| Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas | Q35094629 | ||
| Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. | Q35098046 | ||
| Complement activation determines the therapeutic activity of rituximab in vivo. | Q47745204 | ||
| P433 | issue | 9 | |
| P921 | main subject | antibody | Q79460 |
| ovarian cancer | Q172341 | ||
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1623-1630 | |
| P577 | publication date | 2009-06-01 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. | |
| P478 | volume | 100 |
| Q127380493 | CHO/CLDN3 |
| Q127380494 | CHO/CLDN4 |
| Q127380495 | CHO/CLDN5 |
| Q127380496 | CHO/CLDN6 |
| Q127380497 | CHO/CLDN9 |
| Q127382519 | KM3900 |
| Q39298958 | A novel role for junctional adhesion molecule-A in tumor proliferation: modulation by an anti-JAM-A monoclonal antibody |
| Q33826108 | A novel screening system for claudin binder using baculoviral display |
| Q38410220 | An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors |
| Q41948460 | An improved and robust DNA immunization method to develop antibodies against extracellular loops of multi-transmembrane proteins |
| Q55185636 | Analysis of the effect of promoter type and skin pretreatment on antigen expression and antibody response after gene gun-based immunization. |
| Q39491260 | Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma |
| Q38245421 | Dissecting the role of polarity regulators in cancer through the use of mouse models. |
| Q36796253 | Distinct claudin expression profiles of hepatocellular carcinoma and metastatic colorectal and pancreatic carcinomas |
| Q37303018 | Efficacy and safety evaluation of claudin-4-targeted antitumor therapy using a human and mouse cross-reactive monoclonal antibody. |
| Q37225107 | Emerging roles of claudins in human cancer |
| Q37866083 | Epithelial cell polarity and tumorigenesis: new perspectives for cancer detection and treatment |
| Q35971814 | Epithelial-mesenchymal transition in ovarian carcinoma |
| Q36544167 | Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery |
| Q39628515 | Expression of claudin-4 (CLDN4) mRNA in intraductal papillary mucinous neoplasms of the pancreas. |
| Q41465118 | Expression of hnRNPK & Claudin-4 in HCV-Induced Early HCC and Adjacent Liver Tissue |
| Q47104566 | Identification of claudin-4 binder that attenuates tight junction barrier function by TR-FRET-based screening assay |
| Q45980241 | Immunologic and chemical targeting of the tight-junction protein Claudin-6 eliminates tumorigenic human pluripotent stem cells. |
| Q58779429 | Lipolysis-stimulated lipoprotein receptor overexpression is a novel predictor of poor clinical prognosis and a potential therapeutic target in gastric cancer |
| Q26787279 | Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis |
| Q36828937 | Polarity proteins as regulators of cell junction complexes: implications for breast cancer |
| Q92703058 | Potential for Tight Junction Protein-Directed Drug Development Using Claudin Binders and Angubindin-1 |
| Q38021496 | Proof of concept for claudin-targeted drug development |
| Q39336324 | Regulation of tight junctions in human normal pancreatic duct epithelial cells and cancer cells |
| Q38026601 | Targeting claudin-4 in human pancreatic cancer |
| Q37813173 | The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma |
| Q48002827 | The prognostic role of claudins in head and neck squamous cell carcinomas |
| Q55483367 | Therapeutic antibodies for the treatment of pancreatic cancer. |
| Q39290976 | Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma |
| Q57294408 | Tight junction proteins in gastrointestinal and liver disease |
| Q34033442 | Transcriptional control of tight junction proteins via a protein kinase C signal pathway in human telomerase reverse transcriptase-transfected human pancreatic duct epithelial cells |
| Q39580311 | Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA methylation in human pancreatic cancer cells |
| Q38199103 | Trends in drug delivery through tissue barriers containing tight junctions. |
Search more.